Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Debt: 2022-2025

Historic Total Debt for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $50.9 million.

  • Taysha Gene Therapies' Total Debt rose 18.34% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 18.34%. This contributed to the annual value of $43.9 million for FY2024, which is 8.48% up from last year.
  • Taysha Gene Therapies' Total Debt amounted to $50.9 million in Q3 2025, which was up 23.88% from $41.1 million recorded in Q2 2025.
  • Taysha Gene Therapies' Total Debt's 5-year high stood at $179.1 million during Q3 2023, with a 5-year trough of $37.4 million in Q1 2022.
  • In the last 3 years, Taysha Gene Therapies' Total Debt had a median value of $41.1 million in 2025 and averaged $54.2 million.
  • Its Total Debt has fluctuated over the past 5 years, first spiked by 374.10% in 2023, then slumped by 76.00% in 2024.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Total Debt stood at $38.0 million in 2022, then climbed by 6.69% to $40.5 million in 2023, then grew by 8.48% to $43.9 million in 2024, then rose by 18.34% to $50.9 million in 2025.
  • Its Total Debt was $50.9 million in Q3 2025, compared to $41.1 million in Q2 2025 and $42.5 million in Q1 2025.